scispace - formally typeset
F

Filip K. Knop

Researcher at University of Copenhagen

Publications -  523
Citations -  17834

Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.

Papers
More filters
Journal ArticleDOI

Weight gain on antipsychotics - A perfect storm of complex pathophysiology and psychopharmacology.

TL;DR: The onset of schizophrenia typically occurs in early adulthood, and as the course of illness is often chronic, long-term or even lifelong treatment with antipsychotic medication will often be needed as discussed by the authors.
Journal ArticleDOI

Signs of a Glucose and Insulin-Independent Gut-Bone Axis and Aberrant Bone Homeostasis in Type 1 Diabetes.

TL;DR: In this article , the effect of OGTT and IV glucose infusion on the bone resorption and formation markers in individuals with type 1 diabetes and healthy controls was investigated by using case-control data.

Ckd. pathophysiology, progression and risk factors

TL;DR: In this article , the authors propose a method to solve the problem of "uniformity" and "uncertainty" in the context of health care.i.i295
Journal Article

[Dyslipidaemia in patients with mental illness].

TL;DR: Attention towards early identification of dyslipidaemia, close monitoring, and a low threshold for initiating treatment with lifestyle interventions and lipid-lowering agents are warranted in patients with mental illness.
Journal ArticleDOI

Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)

TL;DR: In this paper , the authors investigated the long-term effects of add-on treatment with semaglutide once a week versus placebo on the metabolic status in pre-diabetic (glycated haemoglobin A1c (HbA1c) 35-47 mmol/mol (5.4%−6.4%) and diabetic patients diagnosed with a schizophrenia spectrum disorder who initiated clozapine or olanzapine treatment within the last 60 months.